John Langenheim

TitleAsst Professor
InstitutionThomas Jefferson University
DepartmentCancer Biology
Address233 S. 10th Street
Philadelphia PA 19107
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Kameyama H, Dondapati P, Simmons R, Leslie M, Langenheim JF, Sun Y, Yi M, Rottschaefer A, Pathak R, Nuguri S, Fung KM, Tsaih SW, Chervoneva I, Rui H, Tanaka T. Needle biopsy accelerates pro-metastatic changes and systemic dissemination in breast cancer: Implications for mortality by surgery delay. Cell Rep Med. 2023 Dec 19; 4(12):101330. PMID: 38118415.
      Citations:    
    2. Chervoneva I, Peck AR, Sun Y, Yi M, Udhane SS, Langenheim JF, Girondo MA, Jorns JM, Chaudhary LN, Kamaraju S, Bergom C, Flister MJ, Hooke JA, Kovatich AJ, Shriver CD, Hu H, Palazzo JP, Bibbo M, Hyslop T, Nevalainen MT, Pestell RG, Fuchs SY, Mitchell EP, Rui H. High PD-L2 Predicts Early Recurrence of ER-Positive Breast Cancer. JCO Precis Oncol. 2023 Jan; 7:e2100498. PMID: 36652667.
      Citations:    
    3. McFall T, Trogdon M, Guizar AC, Langenheim JF, Sisk-Hackworth L, Stites EC. Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP. NPJ Precis Oncol. 2022 Nov 23; 6(1):86. PMID: 36418474.
      Citations:    
    4. Sun Y, Yang N, Utama FE, Udhane SS, Zhang J, Peck AR, Yanac A, Duffey K, Langenheim JF, Udhane V, Xia G, Peterson JF, Jorns JM, Nevalainen MT, Rouet R, Schofield P, Christ D, Ormandy CJ, Rosenberg AL, Chervoneva I, Tsaih SW, Flister MJ, Fuchs SY, Wagner KU, Rui H. NSG-Pro mouse model for uncovering resistance mechanisms and unique vulnerabilities in human luminal breast cancers. Sci Adv. 2021 Sep 17; 7(38):eabc8145. PMID: 34524841.
      Citations:    
    5. Sun Y, Ge L, Udhane SS, Langenheim JF, Rau MJ, Patton MD, Gallan AJ, Felix JC, Rui H. Sensitive and Specific Immunohistochemistry Protocol for Nucleocapsid Protein from All Common SARS-CoV-2 Virus Strains in Formalin-Fixed, Paraffin Embedded Tissues. Methods Protoc. 2021 Jul 10; 4(3). PMID: 34287344.
      Citations:    
    6. Felix JC, Sheinin YM, Suster D, Ronen N, Ratiani M, Vanden Heuvel T, Winge E, Patton MD, Rau MJ, Ge L, Sun Y, Udhane SS, Langenheim JF, Rui H. Diffuse interstitial pneumonia-like/macrophage activation syndrome-like changes in patients with COVID-19 correlate with length of illness. Ann Diagn Pathol. 2021 Aug; 53:151744. PMID: 33991784.
      Citations:    
    7. Tran TH, Utama FE, Sato T, Peck AR, Langenheim JF, Udhane SS, Sun Y, Liu C, Girondo MA, Kovatich AJ, Hooke JA, Shriver CD, Hu H, Palazzo JP, Bibbo M, Auer PW, Flister MJ, Hyslop T, Mitchell EP, Chervoneva I, Rui H. Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling. Clin Cancer Res. 2018 Aug 10. PMID: 30097435.
      Citations:    
    8. Liu Y, Zhang Y, Jiang J, Lobie PE, Paulmurugan R, Langenheim JF, Chen WY, Zinn KR, Frank SJ. GHR/PRLR Heteromultimer Is Composed of GHR Homodimers and PRLR Homodimers. Mol Endocrinol. 2016 May; 30(5):504-17. PMID: 27003442.
      Citations:    
    9. Kim BG, Yoo JY, Kim TH, Shin JH, Langenheim JF, Ferguson SD, Fazleabas AT, Young SL, Lessey BA, Jeong JW. Aberrant activation of signal transducer and activator of transcription-3 (STAT3) signaling in endometriosis. Hum Reprod. 2015 May; 30(5):1069-78. PMID: 25750101.
      Citations:    
    10. Liu Y, Berry PA, Zhang Y, Jiang J, Lobie PE, Paulmurugan R, Langenheim JF, Chen WY, Zinn KR, Frank SJ. Dynamic analysis of GH receptor conformational changes by split luciferase complementation. Mol Endocrinol. 2014 Nov; 28(11):1807-19. PMID: 25188449.
      Citations:    
    11. Xu J, Sun D, Jiang J, Deng L, Zhang Y, Yu H, Bahl D, Langenheim JF, Chen WY, Fuchs SY, Frank SJ. The role of prolactin receptor in GH signaling in breast cancer cells. Mol Endocrinol. 2013 Feb; 27(2):266-79. PMID: 23192981.
      Citations:    
    12. Xu C, Langenheim JF, Chen WY. Stromal-epithelial interactions modulate cross-talk between prolactin receptor and HER2/Neu in breast cancer. Breast Cancer Res Treat. 2012 Jul; 134(1):157-69. PMID: 22270933.
      Citations:    
    13. Xu J, Zhang Y, Berry PA, Jiang J, Lobie PE, Langenheim JF, Chen WY, Frank SJ. Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex. Mol Endocrinol. 2011 Apr; 25(4):597-610. PMID: 21310852.
      Citations:    
    14. Langenheim JF, Chen WY. Improving the pharmacokinetics/pharmacodynamics of prolactin, GH, and their antagonists by fusion to a synthetic albumin-binding peptide. J Endocrinol. 2009 Dec; 203(3):375-87. PMID: 19770179.
      Citations:    
    15. Tomblyn S, Springs AE, Langenheim JF, Chen WY. Combination therapy using three novel prolactin receptor antagonist-based fusion proteins effectively inhibits tumor recurrence and metastasis in HER2/neu transgenic mice. Int J Oncol. 2009 Apr; 34(4):1139-46. PMID: 19287973.
      Citations:    
    16. Langenheim JF, Chen WY. Development of a novel ligand that activates JAK2/STAT5 signaling through a heterodimer of prolactin receptor and growth hormone receptor. J Recept Signal Transduct Res. 2009; 29(2):107-12. PMID: 19519175.
      Citations:    
    17. Yang N, Langenheim JF, Wang X, Jiang J, Chen WY, Frank SJ. Activation of growth hormone receptors by growth hormone and growth hormone antagonist dimers: insights into receptor triggering. Mol Endocrinol. 2008 Apr; 22(4):978-88. PMID: 18096690.
      Citations:    
    18. Scotti ML, Langenheim JF, Tomblyn S, Springs AE, Chen WY. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells. Breast Cancer Res Treat. 2008 Sep; 111(2):241-50. PMID: 17955362.
      Citations:    
    19. Langenheim JF, Tan D, Walker AM, Chen WY. Two wrongs can make a right: dimers of prolactin and growth hormone receptor antagonists behave as agonists. Mol Endocrinol. 2006 Mar; 20(3):661-74. PMID: 16269515.
      Citations:    
    20. Tomblyn S, Langenheim JF, Jacquemart IC, Holle E, Chen WY. The role of human prolactin and its antagonist, G129R, in mammary gland development and DMBA-initiated tumorigenesis in transgenic mice. Int J Oncol. 2005 Nov; 27(5):1381-9. PMID: 16211235.
      Citations:    
    21. Langenheim JF, Chen WY. Development of a prolactin receptor-targeting fusion toxin using a prolactin antagonist and a recombinant form of Pseudomonas exotoxin A. Breast Cancer Res Treat. 2005 Apr; 90(3):281-93. PMID: 15830142.
      Citations:    
    Langenheim's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (114)
    Explore
    _
    Co-Authors (7)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _